Related Experiment Video
Updated: Mar 11, 2026
09:12
Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart
Published on: July 29, 2018
8.6K
Silencing Genes in the Heart
Henry Fechner1, Roland Vetter2, Jens Kurreck3
1Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, Gustav-Meyer-Allee 25, 13355, Berlin, Germany. henry.fechner@tu-berlin.de.
Methods in Molecular Biology (Clifton, N.J.)
|December 3, 2016
Summary
This study demonstrates a novel method for silencing cardiac genes using adeno-associated virus (AAV) vectors carrying small hairpin RNAs (shRNAs) or artificial microRNAs (amiRNAs). This approach overcomes challenges in delivering RNA interference (RNAi) molecules to heart cells for potential cardiac disease therapies.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Gene Therapy
Background:
- RNA interference (RNAi) shows promise for treating cardiac diseases by silencing specific genes.
- Primary cardiomyocytes and the heart are resistant to conventional small interfering RNA (siRNA) transfection.
- Adeno-associated virus (AAV) vectors offer a potential solution for delivering RNAi inducers to cardiac cells.
Purpose of the Study:
- To develop and demonstrate a method for silencing cardiac genes using AAV-delivered shRNAs and amiRNAs.
- To provide a detailed protocol for generating and producing AAV vectors for cardiac gene silencing.
- To establish a method for transducing primary neonatal rat cardiomyocytes (PNRC) with AAV vectors.
Main Methods:
- Generation and cloning of shRNAs and amiRNAs targeting the cardiac protein phospholamban.
- Construction of AAV shuttle plasmids with self-complementary vector genomes.
- Production and purification of AAV vectors using roller bottles, iodixanol gradient centrifugation, and filter concentration.
- Preparation of PNRC, transduction with AAV vectors, and subsequent cell culture maintenance.
Main Results:
- Successful generation of shRNA and amiRNA constructs targeting phospholamban.
- Efficient production and purification of functional AAV vectors.
- Demonstrated transduction of PNRC with AAV vectors, enabling gene silencing.
Conclusions:
- AAV-mediated delivery of shRNAs and amiRNAs is an effective strategy to overcome resistance to siRNA transfection in cardiomyocytes.
- The described methods provide a robust platform for generating and applying AAV vectors for cardiac gene silencing.
- This approach holds potential for developing novel RNAi-based therapies for cardiac diseases.
